Imperial College London
Portrait Picture

Professor Hashim Ahmed

Faculty of Medicine, Department of Surgery & Cancer

Chair in Urology (Clinical)
 
 
 
//

Contact

 

hashim.ahmed

 
 
//

Location

 

5L28Lab BlockCharing Cross Campus

//

Summary

 

Publications

Citation

BibTex format

@article{Kanthabalan:2017:10.1111/bju.13831,
author = {Kanthabalan, A and Peters, M and Van, Vulpen M and McCartan, N and Hindley, RG and Emara, A and Moore, CM and Arya, M and Emberton, M and Ahmed, HU},
doi = {10.1111/bju.13831},
journal = {BJU International},
pages = {246--256},
title = {Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer},
url = {http://dx.doi.org/10.1111/bju.13831},
volume = {120},
year = {2017}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - ObjectiveTo assess short- to medium-term cancer control rates and side effects of focal salvage high- intensity focused ultrasound (HIFU).Materials and MethodsA retrospective registry analysis identified 150 men who underwent focal salvage HIFU (FS-HIFU) (Sonablate 500) between November 2006 and August 2015. Metastatic disease was excluded by nodal assessment on the pelvic MRI, a radioisotope bone scan and positron-emission tomography (PET) imaging (choline-18F-fluorodeoxyglucose PET or choline PET-CT). In our current clinical practice, metastatic disease must be excluded by both choline PET and bone scan. Localization of cancer was carried out using multiparametric MRI of the prostate (T2-weighted, diffusion-weighted and dynamic contrast-enhanced imaging) with systematic or template prostate mapping biopsies. The primary outcome was a composite failure incorporating biochemical failure (BCF) and/or positive localized or distant imaging results and/or positive biopsy and/or systemic therapy and/or metastases/prostate cancer-specific death. The secondary outcome was BCF using the Phoenix-ASTRO definition (prostate-specific antigen [PSA] nadir + 2 ng/mL). We used Kaplan–Meier analysis and Cox proportional hazards regression to quantify the effect of the determinants on the endpoints.ResultsThe mean (standard deviation [sd]) patient age at focal salvage HIFU was 69.8 (6.1) years and the median (interquartile range [IQR]) PSA pre-focal salvage HIFU was 5.5 (3.6–7.9) ng/mL. The median (IQR) follow-up was 35 (22–52) months. Patients were classified as having low- 2.7% (4/150), intermediate- 39.3% (59/150) and high-risk disease 41.3% (62/150) according to D'Amico classification, prior to focal salvage HIFU. Composite failure occurred in 61% of patients (91/150) and BCF occurred in 51.3% (77/150). The Kaplan–Meier composite endpoint-free survival (CEFS) rate at 3 years was 40% (95% confidence interval [CI] 31–50) for the entire group. Kaplan&nd
AU  - Kanthabalan,A
AU  - Peters,M
AU  - Van,Vulpen M
AU  - McCartan,N
AU  - Hindley,RG
AU  - Emara,A
AU  - Moore,CM
AU  - Arya,M
AU  - Emberton,M
AU  - Ahmed,HU
DO  - 10.1111/bju.13831
EP  - 256
PY  - 2017///
SN  - 1464-4096
SP  - 246
TI  - Focal salvage high-intensity focused ultrasound in radiorecurrent prostate cancer
T2  - BJU International
UR  - http://dx.doi.org/10.1111/bju.13831
UR  - http://hdl.handle.net/10044/1/53863
VL  - 120
ER  -
Download